Knight Therapeutics ( (KHTRF) ) has released its Q3 earnings. Here is a breakdown of the information Knight Therapeutics presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Knight Therapeutics Inc., a specialty pharmaceutical company based in Montreal, focuses on acquiring, in-licensing, and commercializing pharmaceutical products across Canada and Latin America. The company recently reported its financial results for the third quarter of 2025, highlighting record-high quarterly revenues and adjusted EBITDA since its inception. Knight Therapeutics also increased its financial guidance for the year, reflecting strong performance and strategic growth initiatives.
In the third quarter of 2025, Knight Therapeutics achieved revenues of $121.5 million, marking a 32% increase compared to the same period last year. This growth was primarily driven by the integration of the Paladin and Sumitomo portfolios and the expansion of key promoted products. Despite the revenue growth, the company reported a net loss of $3.8 million, a significant decline from a net income of $85,000 in the previous year, largely due to increased operating expenses and hyperinflation impacts in Argentina.
The company reported an adjusted EBITDA of $21 million, a 56% increase from the previous year, and adjusted EBITDA per share rose by 62%. Knight’s strategic initiatives included launching several new products in Canada and Latin America, expanding its credit facility, and increasing its share repurchase program. The company’s innovative promoted portfolio also delivered 12% organic growth on a constant currency basis.
Looking ahead, Knight Therapeutics has raised its financial outlook for 2025, expecting revenues between $430 million and $440 million and adjusted EBITDA as a percentage of revenues to be between 13.5% and 14.5%. The company remains focused on executing its growth strategy, despite challenges such as regulatory setbacks and hyperinflation impacts, and aims to continue expanding its product offerings and market presence.